<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332811</url>
  </required_header>
  <id_info>
    <org_study_id>SVCARB10012</org_study_id>
    <secondary_id>U1111-1160-6394</secondary_id>
    <nct_id>NCT02332811</nct_id>
  </id_info>
  <brief_title>An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets &amp; Powder in Hyperphosphatemic CKD Patients</brief_title>
  <acronym>TOSCANA</acronym>
  <official_title>An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets &amp; Powder in Hyperphosphatemic Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      Evaluate the reduction in serum phosphorus from baseline to end of study with Sevelamer&#xD;
      carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD)&#xD;
      patients both on haemodialysis and not on dialysis&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      Evaluate the safety on the basis of adverse events, changes in laboratory values and vital&#xD;
      signs from baseline (Day 0) to Day 56 (End of treatment/ End of Study)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      10 weeks including, 2 weeks wash-out period and 8 weeks study treatment period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction in serum phosphorus from baseline to end of study with Sevelamer carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD) patients both on haemodialysis and not on dialysis</measure>
    <time_frame>up to 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Renal Failure Chronic</condition>
  <arm_group>
    <arm_group_label>CKD patients not on dialysis 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer carbonate 800 mg in tabs 3 times per day with meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD patients not on dialysis 2.4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer carbonate 2.4 g powder carbonate per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD patients on dialysis 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer carbonate 800 mg in tabs 3 times per day with meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD patients on dialysis 2.4 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer carbonate 2.4 g powder carbonate per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer carbonate 800mg</intervention_name>
    <description>Pharmaceutical form:tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>CKD patients not on dialysis 800 mg</arm_group_label>
    <arm_group_label>CKD patients on dialysis 800 mg</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer carbonate 2.4 g</intervention_name>
    <description>Pharmaceutical form:powder&#xD;
Route of administration: oral</description>
    <arm_group_label>CKD patients not on dialysis 2.4 g</arm_group_label>
    <arm_group_label>CKD patients on dialysis 2.4 g</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        Men or women 18 years of age or older suffering from CKD not on dialysis or on a stable&#xD;
        haemodialysis regimen&#xD;
&#xD;
          -  If currently on phosphate binder(s), willing to stop this and enter a 2 week washout&#xD;
             period&#xD;
&#xD;
          -  Willing to avoid any intentional changes in diet such as fasting or dieting&#xD;
&#xD;
          -  Have the following laboratory measurement:&#xD;
&#xD;
               -  iPTH â‰¤ 1000 pg/mL at screening (including results obtained within 60 days prior&#xD;
                  to screening)&#xD;
&#xD;
               -  If not taking a phosphate binder, a serum phosphorus measurement &gt;5.5 mg/dL (1.78&#xD;
                  mmol/L) at Screening (Visit 1).&#xD;
&#xD;
               -  If taking a phosphate binder at screening, a serum phosphorus measurement &gt; 5.5&#xD;
                  mg/dL (1.78 mmol/L) after the two-weeks washout period at Visit 1a (Day 0).&#xD;
&#xD;
          -  Willing and able to take Sevelamer carbonate alone as a phosphate binder for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Willing and able to avoid antacids and phosphate binders containing aluminum,&#xD;
             magnesium, calcium or lanthanum for the duration of the study&#xD;
&#xD;
          -  Willing and able to maintain screening doses of vitamin D, and/or cinacalcet for the&#xD;
             duration of the study, except for safety reasons&#xD;
&#xD;
          -  If female and childbearing potential (pre-menopausal and not surgically sterile),&#xD;
             willing to use an effective contraceptive method throughout study, which includes&#xD;
             barrier methods, hormones, or intrauterine devices&#xD;
&#xD;
          -  For patients not on dialysis expecting not to initiate dialysis for the duration of&#xD;
             this study&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Has not participated in any other investigational drug studies within 30 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Level of understanding and willingness to cooperate with all visits and procedures as&#xD;
             described by the study personnel&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Active dysphagia or swallowing disorder&#xD;
&#xD;
          -  Predisposition or current bowel obstruction,&#xD;
&#xD;
          -  Severe gastrointestinal (GI) motility disorders including severe constipation&#xD;
&#xD;
          -  Active ethanol or drug abuse, excluding tobacco use&#xD;
&#xD;
          -  Use of anti-arrhythmic or anti-seizure medications for arrhythmia or seizure&#xD;
             disorders.&#xD;
&#xD;
          -  In the opinion of the investigator, patient has poorly controlled diabetes mellitus,&#xD;
             poorly controlled hypertension, active vasculitis, HIV infection, or any clinically&#xD;
             significant unstable medical condition&#xD;
&#xD;
          -  Planned renal transplant or parathyroidectomy within 3 months of Visit 1&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Evidence of active malignancy except for basal cell carcinoma of the skin&#xD;
&#xD;
          -  Unable to comply with the requirements of the study&#xD;
&#xD;
          -  Known hypersensitivity to sevelamer or any constituents of the study drug&#xD;
&#xD;
          -  Any other condition, which in the opinion of the investigator will prohibit the&#xD;
             patient's inclusion in the study&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russia</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

